Breaking News Instant updates and real-time market news.

ILMN

Illumina

$184.85

0.36 (0.20%)

, PACB

Pacific Biosciences

$9.05

0.18 (2.03%)

13:58
10/11/16
10/11
13:58
10/11/16
13:58

Illumina plunges after cutting estimated Q3 revenue view

Shares of Illumina (ILMN) plunged in afternoon trading after the biotechnology company cut its estimated revenue view for the third quarter and provided revenue guidance for the fourth quarter. Q3 REVENUE: After the market close yesterday, Illumina said that estimated revenue for Q3 is approximately $607M, marking a 10% increase compared to $550M in the third quarter of 2015, but falling short of the company's previous Q3 revenue guidance of $625M-$630M for the quarter. Analysts expect the company to report Q3 revenue of $628.06M. Illumina said that the shortfall in Q3 revenue was a result of a larger-than-anticipated year-over-year decline in high throughput sequencing instruments. In addition, the company said it expects Q4 revenue to be flat to slightly up sequentially, compared to analysts' estimates of $684.35M. EXECUTIVE COMMENTARY: On a conference call regarding the company's Q3 preannouncement, Illumina president and chief executive officer Francis deSouza said that HiSeq 2500 and 400 orders in the Americas have been lower than expected and that the company closed one less HiSeq X system deal than expected, resulting in a shipment figure of 26 X units during the quarter. The CEO also noted that Illumina is no longer counting on the uptick in high-throughput sequencing instruments and that there are a number of large binary deals that "may or may not" close during during the quarter. STREET RESEARCH: Following the pre-announcement, Citi analyst Daniel Arias downgraded Illumina to Neutral from Buy and cut his price target on shares to $140, noting that the preliminary Q3 revenue figure marked the company's fourth miss in six quarters. Arias said that "forecasting capabilities have clearly diminished" and that the firm would not be surprised to see the hit the $110-$120 range today. Janney Capital analyst Paul Knight also downgraded Illumina to Sell from Neutral, saying that lack of visibility in whole genome sequencing sales and the continued investment in diagnostics with Helix and Grail will constrain profitability. The analyst added that he believes consumable growth at the company could continue to decelerate. In addition, Wells Fargo, which holds a Market Perform rating on the stock, cut its fiscal 2016 and 2017 EPS views for Illumina to $3.30 and $3.65 from $3.51 and $4.08, respectively, and cut its valuation range to $135-$140 from $145-$155. The firm noted that the news marked the third time in five quarters that Illumina negatively pre-announced and that the company has presented a different narrative every quarter. The firm added that it believes Illumina is experiencing the "growing pains" of a company shifting from the mature academic research market to the more nascent but also more challenging clinical market, which could mean slower growth and more limited profitability. Piper Jaffray analyst William Quirk kept an Overweight rating on Illumina, but cut his price target on the shares to $150 from $163, saying that the selloff in shares could be a buying opportunity. The analyst said that HiSeq X channel chicks indicated that the pipeline remains very strong at 95 systems, with a majority driven by the Chinese precision medicine program. PRICE ACTION: In afternoon trading, Illumina shares dropped nearly 26% to $137.57. OTHERS TO WATCH: Biotech rivals Pacific Biosciences of California (PACB) and Qiagen also fell in afternoon trading.

ILMN

Illumina

$184.85

0.36 (0.20%)

PACB

Pacific Biosciences

$9.05

0.18 (2.03%)

QGEN

QIAGEN

$27.57

0.19 (0.69%)

  • 01

    Nov

  • 02

    Nov

ILMN Illumina
$184.85

0.36 (0.20%)

10/11/16
PIPR
10/11/16
NO CHANGE
Target $150
PIPR
Overweight
Illumina selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst William Quirk recommends using today's selloff in shares of Illumina as a buying opportunity. The stock traded down 24% last night after the company reported preliminary Q3 revenue of $607M, below the Street's $628.3M estimate. A lower number of HiSeq 2500/4000 installs as well as a HiSeq X Ten placement slip drove the revenue miss, Quirk tells investors in a research note. He notes, however, that his HiSeq X checks found the pipeline remains "very strong" at 95 systems, with a majority driven by the Chinese precision medicine program. He views $130 as a "technical floor" for the shares and dropped his price target for Illumina to $150 from $163. Quirk keeps an Overweight rating on the name.
10/11/16
SBSH
10/11/16
DOWNGRADE
Target $140
SBSH
Neutral
Illumina downgraded to Neutral from Buy at Citi
Citi analyst Daniel Arias downgraded Illumina to Neutral saying last night's preannouncement marked the company's fourth miss in six quarters. "Forecasting capabilities have clearly diminished," Arias tells investors in a research note. He lowered his price target for the shares to $140 and thinks the stock could hit the $110-$120 range today. Illumina is trading down $48.59, or 26%, to $136.26 in the pre-market.
10/11/16
JANY
10/11/16
DOWNGRADE
JANY
Sell
Illumina downgraded to Sell from Neutral at Janney Capital
10/11/16
10/11/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comerica (CMA) downgraded to Market Perform from Outperform at FBR Capital with analyst Bob Ramsey citing valuation following the recent strength in the shares. 2. Charter downgraded to Neutral from Buy at MoffettNathanson with analyst Craig Moffett saying shares have risen sharply year-to-date, along with consensus estimates, and views shares as fairly valued. 3. BHP Billiton (BHP) downgraded to Neutral from Buy at UBS with the firm citing its expectations for lower iron ore and coal prices over the next six months. 4. Illumina (ILMN) downgraded to Sell from Neutral at Janney Capital and to Neutral from Buy at Citi. 5. KBR (KBR) downgraded to Sell from Neutral at Goldman with analyst Jerry Revich citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PACB Pacific Biosciences
$9.05

0.18 (2.03%)

08/18/16
CANT
08/18/16
NO CHANGE
Target $165
CANT
Speculative Buy
Thermo Fisher unlikely to acquire Illumina, says Cantor
Cantor Fitzgerald analyst Bryan Brokmeier believes it is unlikely that Thermo Fisher (TMO) will attempt to acquire Illumina (ILMN). Even if Thermo were to attempt a deal, the merger would be unlikely to close, Brokmeier tells investors in an intraday research note. If Illumina is a willing seller, however, Roche (RHHBY) may reconsider a bid, the analyst contends. He recommends investors stay on the sidelines with respect to Illumina shares. Brokmeier has a Hold rating on the name with a $165 price target. The analyst continues to believe Roche is the most likely acquirer of Pacific Biosciences (PACB).
08/04/16
08/04/16
NO CHANGE

On The Fly: After Hours Movers
UP AFTER EARNINGS: Pacific Biosciences (PACB), up 17%... MasTec (MTZ), up 9.6%... Aratana Therapeutics (PETX), up 9.2%... Lion's Gate (LGF), up 6.4%... Priceline (PCLN), up 5.7%... Ubiquiti (UBNT), up 5.5%... MercadoLibre (MELI), up 4.1%... Organovo (ONVO), up 3.9%... Kraft Heinz (KHC), up 3.3%... EOG Resources (EOG), up 2.8%... Monster Beverage (MNST), up 1.2%... TASER (TASR), up 1.2%... Take-Two (TTWO), up 0.9%... Activision Blizzard (ATVI), up 1%... BioMarin (BMRN), up 0.4%. ALSO HIGHER: Egalet (EGLT), up 31.2% after the company announced that an FDA advisory committee recommended approval of its ARYMO ER drug... Rackspace (RAX), up 17.6% after the Wall Street Journal reported that the company was near a takeover deal with a private equity buyer... Osiris (OSIR), up 8.5% after it said that the manuscript from its prospective trial using Grafix was published. DOWN AFTER EARNINGS: Hortonworks (HDP), down 26.2%... PDL BioPharma (PDLI), down 17.5%... FireEye (FEYE), down 15.8%... Sierra Wireless (SWIR), down 15.6%... Aquinox (AQXP), down 14.7%... Zynga (ZNGA), down 9.4%... Universal Display (OLED), down 8.2%... Weight Watchers (WTW), down 7.6%... Zillow Group (Z, ZG), down 5.5%... Arista Networks (ANET), down 4.5%... Noodles & Company (NDLS), down 4.3%... Merrimack (MACK), down 1.7%... Bankrate (RATE), down 1.7%.
04/22/16
CANT
04/22/16
NO CHANGE
CANT
Pacific Biosciences should be bought after strong Q1 results, says Cantor
Cantor recommends that investors buy the shares of Pacific Biosciences after the company reported stronger than expected Q1 results. The firm thinks that the company's increased guidance may be conservative, and it believes that the company could have at least 30 bookings in Q2. Cantor keeps an $18 price target and Buy rating on the shares.
04/18/16
PIPR
04/18/16
NO CHANGE
Target $11
PIPR
Neutral
Pacific Biosciences estimates lowered on Sequel checks at Piper Jaffray
Piper Jaffray analyst William Quirk lowered his Q1 estimates for Pacific Biosciences after his initial round of Sequel channel checks found six placements during the quarter compared to the 17 he modeled. Assuming Roche placed five systems, the Q1 total would come to 11, Quirk tells investors in a research note. The analyst keeps a Neutral rating on the shares with an $11 price target.
QGEN QIAGEN
$27.57

0.19 (0.69%)

11/12/15
STFL
11/12/15
INITIATION
STFL
Hold
QIAGEN initiated with a Hold at Stifel
11/12/15
11/12/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Accuray (ARAY) initiated with a Sell at Citi... Becton Dickinson (BDX) initiated with a Neutral at Citi... Boston Scientific (BSX) initiated with a Buy at Citi... Bruker (BRKR) initiated with a Buy at Stifel... C.R. Bard (BCR) initiated with a Buy at Citi... Cepheid (CPHD) initiated with a Buy at Stifel... CorMedix (CRMD) initiated with a Buy at Rodman & Renshaw... CoreSite Realty (COR) initiated with a Buy at BB&T... Digital Realty (DLR) initiated with a Buy at BB&T... DuPont Fabros (DFT) initiated with a Hold at BB&T... Duke Realty (DRE) initiated with a Hold at BB&T... Edwards Lifesciences (EW) initiated with a Sell at Citi... Electronic Arts (EA) initiated with an Outperform at Oppenheimer... EyeGate (EYEG) initiated with a Buy at Maxim... Glu Mobile (GLUU) initiated with a Perform at Oppenheimer... Integra LifeSciences (IART) initiated with a Buy at Citi... Intuitive Surgical (ISRG) initiated with a Buy at Citi... Mast Therapeutics (MSTX) initiated with a Buy at Maxim... Medgenics (MDGN) initiated with a Buy at Needham... Novocure (NVCR) initiated with a Buy at Evercore ISI... Prologis (PLD) initiated with a Hold at BB&T... QIAGEN (QGEN) initiated with a Hold at Stifel... Rocket Fuel (FUEL) initiated with a Neutral at Boenning & Scattergood... STAG Industrial (STAG) initiated with an Underweight at BB&T... Stryker (SYK) initiated with a Sell at Citi... Tremor Video (TRMR) initiated with an Outperform at Boenning & Scattergood... VOXX (VOXX) initiated with an Outperform at Oppenheimer... Varian Medical (VAR) initiated with a Neutral at Citi... Yahoo (YHOO) initiated with an Outperform at Boenning & Scattergood... YuMe (YUME) initiated with a Neutral at Boenning & Scattergood... Zimmer Biomet (ZBH) initiated with a Sell at Citi.
05/25/16
PIPR
05/25/16
NO CHANGE
PIPR
Neutral
Piper says QIAGEN may need to change or pull GeneReader if Illumina wins suit
Piper Jaffray analyst William Quirk said patent infringement outcomes are hard to predict, but added that Illumina's (ILMN) win at the Patent Trial and Appeal Board increase its chances to prevail in its recently filed infringement lawsuit against Qiagen (QGEN) related to the GeneReader DNA sequencer. If Illumina does win, Qiagen will need to "drastically" alter the product and/or remove it from the market, said Quirk, who keeps a Neutral rating on Qiagen shares.
08/01/16
HSBC
08/01/16
UPGRADE
HSBC
Buy
QIAGEN upgraded to Buy from Hold at HSBC
HSBC analyst Keppeler upgraded QIAGEN to Buy and increased its price target to $27 from $20. The analyst is more constructive on improving trends in Academia/Pharma and expects topline growth to accelerate to 7% in 2017 from 1-4% in 2012-2015 from strong growth drivers that include QiaSymphony instrument and the NGS franchise.

TODAY'S FREE FLY STORIES

ACN

Accenture

$121.23

0.51 (0.42%)

15:17
02/20/17
02/20
15:17
02/20/17
15:17
Hot Stocks
Accenture announces intent to acquire SinnerSchrader »

Accenture announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGG

CGG SA

15:13
02/20/17
02/20
15:13
02/20/17
15:13
Hot Stocks
CGG SA says secures consent from debt holders »

CGG SA CGG announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PI

Impinj

$31.17

-4.19 (-11.85%)

15:05
02/20/17
02/20
15:05
02/20/17
15:05
Hot Stocks
Impinj announces partnership, platform integration with STANLEY Healthcare »

Impinj announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

HRS

Harris

$109.46

0.81 (0.75%)

15:03
02/20/17
02/20
15:03
02/20/17
15:03
Hot Stocks
Harris wins $189M contract with UAE military »

Harris has received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$100.52

-0.3 (-0.30%)

15:01
02/20/17
02/20
15:01
02/20/17
15:01
Hot Stocks
Alibaba announces strategic partnership with Bailian Group »

Alibaba and Chinese…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 19

    Mar

SWIR

Sierra Wireless

$27.80

1.575 (6.01%)

, VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

14:58
02/20/17
02/20
14:58
02/20/17
14:58
Hot Stocks
Sierra Wireless says connected car products selected by Volkswagen »

Sierra Wireless (SWIR)…

SWIR

Sierra Wireless

$27.80

1.575 (6.01%)

VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGNX

Progenics

$10.62

0.08 (0.76%)

, CLMS

Calamos

$8.24

-0.03 (-0.36%)

14:55
02/20/17
02/20
14:55
02/20/17
14:55
Hot Stocks
Progenics to replace Calamos in S&P 600 as of 2/20 close »

Calamos Asset Management…

PGNX

Progenics

$10.62

0.08 (0.76%)

CLMS

Calamos

$8.24

-0.03 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 01

    Mar

SFLY

Shutterfly

$48.06

0.66 (1.39%)

, VASC

Vascular Solutions

14:55
02/20/17
02/20
14:55
02/20/17
14:55
Hot Stocks
Shutterfly to replace Vascular Solutions in S&P 600 as of 2/20 close »

S&P MidCap 400…

SFLY

Shutterfly

$48.06

0.66 (1.39%)

VASC

Vascular Solutions

TFX

Teleflex

$179.91

1.86 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NKTR

Nektar

$13.10

0.12 (0.92%)

, BMY

Bristol-Myers

$54.59

0.31 (0.57%)

14:48
02/20/17
02/20
14:48
02/20/17
14:48
Hot Stocks
Nektar reports Phase 1 data on NKTR-214 in kidney cancer »

Nektar Therapeutics…

NKTR

Nektar

$13.10

0.12 (0.92%)

BMY

Bristol-Myers

$54.59

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

XNCR

Xencor

$24.28

0.5 (2.10%)

14:38
02/20/17
02/20
14:38
02/20/17
14:38
Hot Stocks
Xencor announces data presentation on XmAb5871 »

Xencor announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

RHHBY

Roche

$30.53

0.02 (0.07%)

14:35
02/20/17
02/20
14:35
02/20/17
14:35
Hot Stocks
Genentech reports Phase 2 data on Tecentriq combo in kidney cancer »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 09

    Mar

  • 26

    Jun

RVSB

Riverview Bancorp

$7.50

-0.11 (-1.45%)

14:30
02/20/17
02/20
14:30
02/20/17
14:30
Hot Stocks
Breaking Hot Stocks news story on Riverview Bancorp »

Riverview Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCN

Ocwen

$5.24

0.09 (1.75%)

14:27
02/20/17
02/20
14:27
02/20/17
14:27
Hot Stocks
Ocwen reaches settlement, termination of California consent order »

Ocwen Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SYF

Synchrony

$36.68

-0.17 (-0.46%)

14:07
02/20/17
02/20
14:07
02/20/17
14:07
Periodicals
Synchrony likely to see more gains, Barron's says »

Synchrony "still has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$160.25

-3.52 (-2.15%)

, CI

Cigna

$143.56

-1.77 (-1.22%)

14:05
02/20/17
02/20
14:05
02/20/17
14:05
Periodicals
Merger collapse could get Anthem back on track, Barron's says »

The likely collapse of…

ANTM

Anthem

$160.25

-3.52 (-2.15%)

CI

Cigna

$143.56

-1.77 (-1.22%)

ESRX

Express Scripts

$69.97

0.74 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

QSR

Restaurant Brands

$53.90

0.05 (0.09%)

, PLKI

Popeyes

$66.12

-0.26 (-0.39%)

13:50
02/20/17
02/20
13:50
02/20/17
13:50
Periodicals
Restaurant Brands in advanced talks to buy Popeyes, Bloomberg says »

A deal could be announced…

QSR

Restaurant Brands

$53.90

0.05 (0.09%)

PLKI

Popeyes

$66.12

-0.26 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Mar

AAPL

Apple

$135.72

0.375 (0.28%)

, AMAT

Applied Materials

$35.67

0.49 (1.39%)

13:48
02/20/17
02/20
13:48
02/20/17
13:48
Periodicals
Smartphone design trends could benefit Applied Materials, others, Barron's says »

As Apple (AAPL) and other…

AAPL

Apple

$135.72

0.375 (0.28%)

AMAT

Applied Materials

$35.67

0.49 (1.39%)

OLED

Universal Display

$72.15

0.85 (1.19%)

GLW

Corning

$27.65

-0.06 (-0.22%)

SSNLF

Samsung

LPL

LG Display

$12.39

0.07 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 13

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

  • 28

    Mar

  • 01

    Apr

TOSBF

Toshiba, also use TOSYY

$1.61

-0.182 (-10.17%)

, TOSYY

Toshiba, also use TOSBF

$9.55

-1.085 (-10.21%)

13:32
02/20/17
02/20
13:32
02/20/17
13:32
Periodicals
Toshiba could have 50% upside, Barron's says »

Toshiba shares are…

TOSBF

Toshiba, also use TOSYY

$1.61

-0.182 (-10.17%)

TOSYY

Toshiba, also use TOSBF

$9.55

-1.085 (-10.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIN

DineEquity

$60.14

-6.41 (-9.63%)

13:27
02/20/17
02/20
13:27
02/20/17
13:27
Periodicals
DineEquity remains challenged, Barron's says »

"Problems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

HD

Home Depot

$143.00

1.46 (1.03%)

13:09
02/20/17
02/20
13:09
02/20/17
13:09
Periodicals
Home Depot looks healthy into earnings report, Barron's says »

Home Depot remains the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 15

    Mar

ADNT

Adient

$64.01

-0.69 (-1.07%)

, JCI

Johnson Controls

$41.91

0.23 (0.55%)

12:58
02/20/17
02/20
12:58
02/20/17
12:58
Periodicals
Adient could offer 35% upside, Barron's says »

Shares of Adient (ADNT)…

ADNT

Adient

$64.01

-0.69 (-1.07%)

JCI

Johnson Controls

$41.91

0.23 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$51.75

0.45 (0.88%)

12:47
02/20/17
02/20
12:47
02/20/17
12:47
Periodicals
Steer clear of Hess Corp, Barron's says »

Hess Corp shares are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

GM

General Motors

$37.22

0.19 (0.51%)

12:33
02/20/17
02/20
12:33
02/20/17
12:33
Periodicals
General Motors stock could reach $50 in a year, Barron's says »

Shares of General Motors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

11:43
02/20/17
02/20
11:43
02/20/17
11:43
Conference/Events
DA Davidson E&C and industrials analysts hold analyst/industry conference call »

E&C, Materials &…

11:38
02/20/17
02/20
11:38
02/20/17
11:38
Conference/Events
DA Davidson technology/software analysts hold analyst/industry conference call »

Technology Analyst…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.